Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Clin Cancer Res. 2021 Sep 13;27(22):6174–6183. doi: 10.1158/1078-0432.CCR-21-0987

Figure 3. Association of OX40 and OX40L with EGFR and KRAS mutations.

Figure 3.

(a) OX40 and (b) OX40L QIF scores (mean ± SD) plotted for EGFR-mutated, KRAS-mutated, and EGFR/KRAS-wildtype cases. Statistical analysis by Kruskal-Wallis test.